1. Clinical & Scientific Overview
Mifepristone (Antiprogestogen — Medical Termination Combi-Pack) (TIP-MED-000247, Reference Code [12.15]) is classified under
Obstetric, Gynaecological & Antifibrinolytic Medicines (Ch 12) as a Synthetic Steroidal Antiprogestogen & Antiglucocorticoid (Progesterone Receptor Antagonist).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.15], p. 162): Mifegest, Mifeprex, Unwanted-Kit (Combi-pack with Misoprostol) — Strengths & Dosage Forms: Tablet: 200 mg (standalone or in Combi-Pack: 1 tablet Mifepristone 200 mg + 4 tablets Misoprostol 200 mcg).
Tablet: 200 mg (standalone or in Combi-Pack: 1 tablet Mifepristone 200 mg + 4 tablets Misoprostol 200 mcg).
3. Mechanism of Action & Pharmacodynamics
Competitively blocks endometrial and myometrial progesterone receptors -> causes decidual necrosis, detachment of conceptus, cervical softening, and sensitization of myometrium to prostaglandins.
4. Therapeutic Indications & Evidence-Supported Uses
- Medical termination of intrauterine pregnancy (in sequential combination with Misoprostol under the MTP Act)
- medical management of early fetal demise
- cervical preparation prior to surgical abortion
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adult: Medical Termination (per MTP Rules / FOGSI guidelines): 200 mg PO single dose on Day 1 under medical supervision, followed 24-48 hours later by Misoprostol 800 mcg (four 200 mcg tablets) buccally/sublingually/vaginally. • Paediatric: Adolescent obstetric care under MTP Act provisions only.
Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Caution in severe renal impairment. • Hepatic: Avoid in severe hepatic impairment.
Renal: Caution in severe renal impairment. • Hepatic: Avoid in severe hepatic impairment.
Renal: Caution in severe renal impairment. • Hepatic: Avoid in severe hepatic impairment.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindications: Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass (Mifepristone does NOT terminate ectopic pregnancy—rupture can be fatal); chronic adrenal failure; inherited porphyria; uncontrolled severe asthma; severe anaemia (Hb <7-8 g/dL) without transfusion access; IUD in situ (must be removed first). • Precautions: MANDATORY INDIAN STATUTORY COMPLIANCE (MTP Amendment Act 2021 & CDSCO Directives): Over-the-counter sale without a qualified Gynaecologist/MTP-certified RMP prescription is strictly illegal; ultrasound/clinical confirmation of intrauterine pregnancy and Rh-typing (Anti-D immunoglobulin within 72h if Rh-negative) are mandatory.
Key Clinical Precautions: Renal: Caution in severe renal impairment. • Hepatic: Avoid in severe hepatic impairment.
8. Adverse Effects Profile
- Uterine cramping, prolonged vaginal spotting/bleeding (9-16 days), nausea, vomiting, dizziness.
- Haemorrhage requiring transfusion or suction evacuation (1-3%), ruptured unrecognised ectopic pregnancy, Clostridium sordellii toxic shock sepsis (rare—presents as afebrile malaise, haemoconcentration, severe leukocytosis).
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CYP3A4 inhibitors (Ketoconazole, Itraconazole, Erythromycin, Grapefruit juice) -> increase mifepristone levels; CYP3A4 inducers (Rifampicin, Phenytoin, Carbamazepine) -> reduce efficacy and cause failed abortion; Corticosteroids (Dexamethasone) -> antiglucocorticoid effect reduces steroid efficacy for 3-4 days
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Take Day-1 tablet (Mifepristone 200 mg) first, then the 4 smaller tablets (Misoprostol) 24-48 hours later as instructed; return immediately for severe abdominal pain with fainting (ectopic alert), soaking >2 pads/hour for 2 hours, or foul discharge/malaise >24 hours after Misoprostol.
- Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Tablet: 200 mg (standalone or in Combi-Pack: 1 tablet Mifepristone 200 mg + 4 tablets Misoprostol 200 mcg).
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.15] (p. 162)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.16] Magnesium Sulphate Injection (Parenteral IV/IM Pritchard & Zuspan Eclampsia Regimen) — Parenteral Anticonvulsant in Eclampsia, Electrolyte Replenisher &
- [12.17] Oxytocin, Methylergometrine Maleate & Carboprost — High-Alert Obstetric Uterotonics (Neurohypophyseal Peptide, Ergot
- [12.16]-CMP163 Isoxsuprine Hydrochloride IP — Parenteral Anticonvulsant in Eclampsia, Electrolyte Replenisher &
- [12.17]-C164 Methylergometrine Maleate — High-Alert Obstetric Uterotonics (Neurohypophyseal Peptide, Ergot